Chronic Vulvovaginal Hypersensitivity: An Underrecognized and Undertreated Disorder by Allergists

Vulvovaginal candidiasis infections are estimated to occur at least once during the lifetime of 75% of the female population. It has been proposed that some women with recurrent vulvovaginal candidiasis (RVVC) develop sensitization to Candida albicans and clinically improve in response to Candida im...

Full description

Bibliographic Details
Main Authors: Jonathan A. Bernstein M.D., Luqman Seidu M.D.
Format: Article
Language:English
Published: SAGE Publishing 2015-03-01
Series:Allergy & Rhinology
Online Access:https://doi.org/10.2500/ar.2015.6.0113
_version_ 1818340319942410240
author Jonathan A. Bernstein M.D.
Luqman Seidu M.D.
author_facet Jonathan A. Bernstein M.D.
Luqman Seidu M.D.
author_sort Jonathan A. Bernstein M.D.
collection DOAJ
description Vulvovaginal candidiasis infections are estimated to occur at least once during the lifetime of 75% of the female population. It has been proposed that some women with recurrent vulvovaginal candidiasis (RVVC) develop sensitization to Candida albicans and clinically improve in response to Candida immunotherapy. Here, we report a case series of 12 women diagnosed with chronic vulvovaginal Candida hypersensitivity subsequently treated with Candida immunotherapy and review potential systemic and localized host immune defense mechanisms involved in C. albicans overgrowth and sensitization. A retrospective review of vulvovaginal Candida hypersensitivity in women who were treated with C. albicans immunotherapy over the past eight years was conducted. Twelve women who qualified for a diagnosis of vulvovaginal Candida hypersensitivity were treated with Candida immunotherapy. Eleven of the 12 (92%) women reported clinical improvement after immunotherapy. The majority of these women were not sensitized to seasonal or perennial aeroallergens and clinically responded to lower concentrations of C. albicans allergen than what has been previously reported. In general, Candida immunotherapy was well tolerated. Chronic vulvovaginal Candida hypersensitivity is an underrecognized disorder by primary care physicians and therefore an undertreated disorder by allergists. A double-blinded, placebo-controlled randomized trial is necessary to firmly establish the efficacy of treatment with Candida immunotherapy. This investigation should be designed to include mechanistic studies that would help to better understand the etiology of this disorder.
first_indexed 2024-12-13T15:41:01Z
format Article
id doaj.art-b79e94d4d5b04f2c9e8df88c8c83d1d2
institution Directory Open Access Journal
issn 2152-6567
language English
last_indexed 2024-12-13T15:41:01Z
publishDate 2015-03-01
publisher SAGE Publishing
record_format Article
series Allergy & Rhinology
spelling doaj.art-b79e94d4d5b04f2c9e8df88c8c83d1d22022-12-21T23:39:50ZengSAGE PublishingAllergy & Rhinology2152-65672015-03-01610.2500/ar.2015.6.0113Chronic Vulvovaginal Hypersensitivity: An Underrecognized and Undertreated Disorder by AllergistsJonathan A. Bernstein M.D.0Luqman Seidu M.D.1Department of Internal Medicine, Division of Immunology/Allergy Section, University of Cincinnati College of MedicineDivision Omni Allergy and Immunology, Atlanta, GeorgiaVulvovaginal candidiasis infections are estimated to occur at least once during the lifetime of 75% of the female population. It has been proposed that some women with recurrent vulvovaginal candidiasis (RVVC) develop sensitization to Candida albicans and clinically improve in response to Candida immunotherapy. Here, we report a case series of 12 women diagnosed with chronic vulvovaginal Candida hypersensitivity subsequently treated with Candida immunotherapy and review potential systemic and localized host immune defense mechanisms involved in C. albicans overgrowth and sensitization. A retrospective review of vulvovaginal Candida hypersensitivity in women who were treated with C. albicans immunotherapy over the past eight years was conducted. Twelve women who qualified for a diagnosis of vulvovaginal Candida hypersensitivity were treated with Candida immunotherapy. Eleven of the 12 (92%) women reported clinical improvement after immunotherapy. The majority of these women were not sensitized to seasonal or perennial aeroallergens and clinically responded to lower concentrations of C. albicans allergen than what has been previously reported. In general, Candida immunotherapy was well tolerated. Chronic vulvovaginal Candida hypersensitivity is an underrecognized disorder by primary care physicians and therefore an undertreated disorder by allergists. A double-blinded, placebo-controlled randomized trial is necessary to firmly establish the efficacy of treatment with Candida immunotherapy. This investigation should be designed to include mechanistic studies that would help to better understand the etiology of this disorder.https://doi.org/10.2500/ar.2015.6.0113
spellingShingle Jonathan A. Bernstein M.D.
Luqman Seidu M.D.
Chronic Vulvovaginal Hypersensitivity: An Underrecognized and Undertreated Disorder by Allergists
Allergy & Rhinology
title Chronic Vulvovaginal Hypersensitivity: An Underrecognized and Undertreated Disorder by Allergists
title_full Chronic Vulvovaginal Hypersensitivity: An Underrecognized and Undertreated Disorder by Allergists
title_fullStr Chronic Vulvovaginal Hypersensitivity: An Underrecognized and Undertreated Disorder by Allergists
title_full_unstemmed Chronic Vulvovaginal Hypersensitivity: An Underrecognized and Undertreated Disorder by Allergists
title_short Chronic Vulvovaginal Hypersensitivity: An Underrecognized and Undertreated Disorder by Allergists
title_sort chronic vulvovaginal hypersensitivity an underrecognized and undertreated disorder by allergists
url https://doi.org/10.2500/ar.2015.6.0113
work_keys_str_mv AT jonathanabernsteinmd chronicvulvovaginalhypersensitivityanunderrecognizedandundertreateddisorderbyallergists
AT luqmanseidumd chronicvulvovaginalhypersensitivityanunderrecognizedandundertreateddisorderbyallergists